LPAR2: Lysophosphatidic Acid Receptor 2
A G protein-coupled receptor mediating LPA signaling in cell proliferation, migration, and cancer progression.
Gene Information Card
| Symbol | LPAR2 |
|---|---|
| Full Name | Lysophosphatidic Acid Receptor 2 |
| Gene Type | protein-coding |
| Chromosomal Location | 19p13.11 |
| NCBI Gene ID | 9170 ncbi.nlm.nih.gov/gene/9170 |
| Ensembl ID | ENSG00000167552 |
| UniProt ID | Q9HBW0 |
| OMIM ID | 605110 |
| HGNC ID | 3167 |
| Aliases | LPA2, EDG4, LPA-2, LPAR2 |
Description
LPAR2 (Lysophosphatidic Acid Receptor 2) is a G protein-coupled receptor that binds lysophosphatidic acid (LPA), a bioactive phospholipid. It mediates diverse cellular responses including proliferation, migration, survival, and cytoskeletal reorganization. LPAR2 is implicated in cancer progression, fibrosis, and neuropathic pain.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Cancer (various types) | LPAR2 overexpression promotes tumor cell proliferation, migration, and invasion via Gi/o and Gq/11 signaling pathways. | PMID: 19145235; COSMIC |
| Pulmonary fibrosis | LPA-LPAR2 signaling activates fibroblast recruitment and survival, contributing to lung fibrosis. | PMID: 18497885; NCBI Gene |
| Neuropathic pain | LPAR2 activation in dorsal root ganglia contributes to pain hypersensitivity after nerve injury. | PMID: 21131953; OMIM |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Heart | 12.3 | Medium |
| Lung | 8.7 | Medium |
| Liver | 6.2 | Low |
| Kidney | 10.1 | Medium |
| Brain | 5.4 | Low |
| Testis | 15.8 | High |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HeLa | 9.5 | Cervical cancer cell line |
| A549 | 11.2 | Lung adenocarcinoma cell line |
| MCF7 | 7.8 | Breast cancer cell line |
| HepG2 | 6.4 | Hepatocellular carcinoma cell line |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.100G>A (p.Gly34Arg) | Missense | <0.1% | Potential loss of function; reduced LPA binding affinity |
| c.457C>T (p.Arg153Trp) | Missense | <0.1% | Unknown functional effect; reported in COSMIC |
| c.784A>G (p.Ile262Val) | Missense | <0.1% | Likely benign; population frequency low |
Mutation functional classification
Loss of Function (LOF)
p.Gly34Arg reduces LPA binding and downstream signaling.
Gain of Function (GOF)
No confirmed gain-of-function mutations reported in LPAR2.
Dominant Negative (DN)
No dominant-negative mutations described for LPAR2.
View complete mutation data：
Gene Ontology (GO)
| • G protein-coupled receptor activity (GO:0004930) | • lysophosphatidic acid receptor activity (GO:0032781) |
| • cell surface receptor signaling pathway (GO:0007166) | • positive regulation of cell migration (GO:0030335) |
| • positive regulation of cell proliferation (GO:0008284) |
Pathways
• LPA signaling pathway (Reactome: R-HSA-419037)
• GPCR downstream signaling (Reactome: R-HSA-388396)
• G alpha (i) signaling events (Reactome: R-HSA-418594)
Protein Summary
LPAR2 is a 351-amino acid integral membrane protein with seven transmembrane domains, typical of class A GPCRs. It couples primarily to Gi/o and Gq/11 proteins, activating MAPK, PI3K/Akt, and Rho pathways. LPAR2 is widely expressed in heart, lung, kidney, and testis, and its dysregulation is linked to cancer and fibrotic diseases.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| LPAR2 Knockout HEK293 Cell Line | EDJ-KQ833 | Human | 9170 | Details Get a Quote |
| LPAR2 Knockout A-549 Cell Line | EDJ-KQ19612 | Human | 9170 | Details Get a Quote |
| LPAR2 Knockout HCT 116 Cell Line | EDJ-KQ19613 | Human | 9170 | Details Get a Quote |
| LPAR2 Knockout HeLa Cell Line | EDJ-KQ19614 | Human | 9170 | Details Get a Quote |
